News & Press
La société développe une nouvelle approche pour lutter contre la Sclérose en Plaques. Elle a été identifiée comme un "champion de la croissance" par une étude réalisée par la "Handelszeitung" et "Le Temps", en collaboration avec l'Institut Statista.
Geneva (Switzerland), 7 February 2017 : (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), announced today the signing of a Cooperative Research and Development Agreement (CRADA) with The National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). The research will evaluate the ability of these antibodies to neutralise a potential causal factor of ALS, the envelope protein of HERV-K (a family of Human Endogenous Retroviruses, HERVs).
Geneva, Switzerland, 31 January 2017 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), reports today on its cash and revenue at December 31, 2016.
Geneva (Switzerland), 3 January 2017: GeNeuro (Euronext Paris: CH0308403085 – GNRO)
- Enrollment completed for CHANGE-MS study ahead of schedule; 6-month top-line results now expected in early 4Q2017
- ANGEL-MS study launched, dosing of first patient expected in April 2017
- U.S. study in secondary progressive MS patients planned for 2H 2017
Results 1-4 of 4